UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorp ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2020 Earnings Conference Call May 6, 2020 8:30 AM ET Company Participants George Elston - Chief Financial Officer and Head-Corporate Development Nancy Lurker - President and Chief Executive Officer Scott Jones - Chief Commercial Officer Dario Paggiarino - Senior Vice President and Chief Medical Officer Conference Call Participants I-Eh Jen - Laidlaw & Company Andrew D'Silva - B. Riley FBR Yi Chen - H.C. Wainwright Operator Good morning. My name is Shannon and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or other jurisdiction of in ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2019 Earnings Conference Call March 5, 2020 8:30 AM ET Company Participants George Elston – Chief Financial Officer and Head-Corporate Development Nancy Lurker – President and Chief Executive Officer Scott Jones – Chief Commercial Officer Dario Paggiarino – Senior Vice President and Chief Medical Officer Conference Call Participants Dana Flanders – Guggenheim Securities Andrew D'Silva – B. Riley FBR I-Eh Jen – Laidlaw & Company Yi Chen – H.C. Wainwright Operat ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2019 Earnings Conference Call November 7, 2019 8:30 AM ET Company Participants Kimberly Minarovich - Investor Relations, Argot Partners Nancy Lurker - President & Chief Executive Officer Scott Jones - Chief Commercial Officer Conference Call Participants Dana Flanders - Guggenheim Andrew D’Silva - B. Riley Edward Marks - H.C. Wainwright Operator Good morning. My name is Sydney, and I will be your conference operator today. At this time, I would like to welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in ...

EyePoint Pharmaceuticals Third Quarter 2019 Financial Results Conference Call November 7, 2019 On Today's Call Prepared Remarks: Kimberly Minarovich, Argot Partners Nancy Lurker, President & Chief Executive Officer Scott Jones, Chief Commercial Officer Joining for Q&A Session: George Elston, CPA, Consultant and Interim Chief Financial Officer Dario Paggiarino, MD, Senior Vice President & Chief Medical Officer 2 Forward Looking Statements SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF ...

业绩总结 - 公司在2018年从股权和债务合作伙伴获得超过8000万美元的资金[3] - 截至2019年6月30日，公司现金为4420万美元[43] - 截至2019年8月5日，公司已发行普通股为1.06亿股[43] 用户数据 - DEXYCU®在术后第一天（POD 1）中，患者眼内压（IOP）低于25 mm Hg的比例为90.1%，而安慰剂组为76.7%[19] - 在术后第三天（POD 3），DEXYCU®组中低于25 mm Hg的患者比例为100.0%，安慰剂组为98.0%[19] - YUTIQ®患者在6个月和12个月的复发率分别为18%和28%，显著低于安慰剂组[32] 新产品和新技术研发 - DEXYCU®于2019年3月12日正式上市，拥有专门的J代码用于报销[24] - YUTIQ®于2019年2月4日上市，专注于慢性非感染性葡萄膜炎的治疗[37] - Durasert™技术已获得FDA批准，用于眼科药物递送[7] - 公司计划在2019年提交YUTIQ®短效治疗的sNDA申请[8] - 公司正在评估与Durasert™和Verisome®技术相关的潜在合作伙伴关系[43] 市场扩张和并购 - 公司收购Icon Bioscience以转型业务并加速增长[46] - 公司正在探索在Medicare Part B中超出白内障套餐的延长报销途径[43] - 目前已有超过4200名患者接受了DEXYCU®注射，275个以上的手术中心完成了培训[27] 负面信息 - 在安全性方面，接受517 mcg DEXYCU®的患者中，63.8%报告有任何不良事件（TEAE），而安慰剂组为46.2%[22] - DEXYCU®组中，眼内压升高的患者比例为13.5%，安慰剂组为8.8%[22] - YUTIQ®的安全性数据显示，视觉敏锐度降低的比例为15%，而安慰剂组为12%[36] 其他新策略和有价值的信息 - 公司已建立强大的领导团队，以推动商业战略和管理销售基础设施[3] - DEXYCU®的有效成分为9%的地塞米松，能够在单次注射后持续释放，检测时间可达22天[16] - DEXYCU®的J代码（J1095）和YUTIQ®的J代码（J7314）已获得[11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo ...